Venture Corporation - UOB Kay Hian 2021-02-25: FY20 Results Preview & Potential Risks For 2021

VENTURE CORPORATION LIMITED (SGX:V03) | SGinvestors.io VENTURE CORPORATION LIMITED (SGX:V03)

Venture Corporation - FY20 Results Preview & Potential Risks For 2021

  • We expect Venture Corp's 2020 earnings to be largely in line with our estimate of S$300m as sequential recovery continues into 4Q20 from further reopening of economies and good demand for customers’ essential products. However, we see three potential key risks for 2021:
    1. delay of new product launches due to weaker market sentiment,
    2. production disruption due to COVID-19 outbreak in Malaysia, and
    3. reduced demand for essential products linked to COVID-19.
  • Maintain BUY on Venture Corp and target price of S$23.76.



Expect 2020 earnings to be largely in line with our estimate of S$300m.

  • To recap, Venture Corp (SGX:V03)’s 9M20 earnings of S$211m forms around 70% of our full-year forecast. Our 4Q20 earnings forecast of S$89m (+11% q-o-q, -8% y-o-y) is expected to reflect sequential growth but decline on a y-o-y basis.
  • The sequential recovery is expected to be driven by factors which impacted 3Q20 like the further reopening of economies and good demand for customers’ essential products.
  • In addition, several key Venture Corp's customers reported a healthy set of 4Q20 results:
    • Broadcomm’s 4Q20 revenue grew 12% y-o-y;
    • Thermo Fisher’s 4Q20 revenue grew 54% y-o-y; and
    • Illumina’s 4Q20 revenue grew 20% q-o-q, flat y-o-y.


Potential delay of product launches due to weaker market sentiment.

  • Venture Corp’s clients may delay new product launches into the later part of the year if market sentiment weakens. For instance, 4Q20 and 1Q21 saw a resurgence in the number of COVID-19 cases around the world, especially in US and EU, key markets of Venture Corp’s clients.

Risk of disruption to production capacity.

  • Although the recently announced two-week movement control order (MCO) for eight states in Malaysia provides flexibility for essential services, such as manufacturing, to continue operations, we believe the resurgence in COVID-19 cases could raise the risk of disruption to production.
  • The Malaysian government ordered all foreign workers to undergo mandatory COVID-19 screening starting 1 Jan 21, including the manufacturing sector. Should Venture Corp's employees test positive, it could lead to a temporary disruption to operations or capacity cuts at its factories. Venture Corp’s presence in Malaysia, which includes Johor and Penang (both of which fall within the MCO states), form 81% of its total site area.


Risk of reduced demand for essential products linked to COVID-19.

  • For 2020, several of Venture Corp’s clients have benefitted from essential products due to COVID-19, especially Thermo Fisher, whose full-year revenue grew 26% y-o-y and majority of the growth was driven by COVID-19-related testing equipment.
  • From its 2021 revenue forecast of 9%, Thermo Fisher expects COVID-19-related testing to contribute 2% growth, while the base business contributes the remaining 7%.


Strong balance sheet and good dividends provide limit for share price downside.

  • As of end-1H20, Venture Corp recorded net cash of S$831m (forming about 15% of its current market cap) and led the pack of US-listed peers which were mostly in net debt positions.
  • More importantly, Venture Corp has consistently paid the same amount of dividends or better than in the preceding year. We expect a dividend of S$0.75 per share this year which translates into an attractive dividend yield of 3.9%.


Venture Corp - Valuation & Recommendation






John Cheong UOB Kay Hian Research | https://research.uobkayhian.com/ 2021-02-25
SGX Stock Analyst Report BUY MAINTAIN BUY 23.760 SAME 23.760



Advertisement



MOST TALKED ABOUT STOCKS / REITS OF THE WEEK



loading.......



ANALYSTS SAY


loading.......